NCT00220064已完成2 期
A Phase II Trial Evaluating Irinotecan With 5_fluorouracil Plus Leucovorin in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 65
- 主要终点
- Disease stabilization rate or tumour marker response
研究概览
简要总结
The objective of this study is to assess the efficacy and toxicity of a 2 weekly regimen containing irinotecan combined with leucovorin-modified 5-fluorouracil in the setting of relapsed or refractory upper gastrointestinal tumours. Patients with locally advanced or metastatic adenocarcinoma originating from the oesophagogastric junction, stomach or pancreas who have previously received chemotherapy and have either failed to respond or who have relapsed after an initial response will be eligible for treatment in this study.
The response rate, failure-free survival and overall survival of treated patients with the two different regimes will be evaluated. Toxicity and quality of life will also be monitored closely.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven adenocarcinoma or squamous cell carcinoma of the Oesophagus, O-G junction, stomach and pancreas, not amenable to surgical resection.
- •Bidimensionally measurable disease, or unidimensional measurable disease accessible by CT scanning, not within previously irradiated areas.
- •Patients with progressive disease during previous chemotherapy treatment or within three months of stopping treatment.
- •At least one previous chemotherapy regimen, given at least 4 weeks prior to inclusion in this study.
- •No previous exposure to irinotecan.
- •Adequate bone marrow function with platelets >100 X 109/L; WBC > 3 X 109/L; Neutrophils > 1.5 X 109/L at the time of study entry.
- •Satisfactory renal function, serum creatinine 135 mol/litre
- •Satisfactory liver function:
- •In the absence of liver metastases:- Bilirubin < 1.25N (N=upper limit of normal range) Hepatic transaminases < 2.5N Prothrombin time < 1.5N
- •In the presence of liver metastases:- Bilirubin < 1.5N Hepatic transaminases < 5N Prothrombin time < 1.5N
- •No uncontrolled medical condition
- •No previous malignant disease except for non-melanotic skin cancer or in-situ carcinoma of the uterine cervix.
- •ECOG performance status of 0, 1 or
- •Predicted life expectancy of > 3 months.
- •Adequate contraceptive precautions
- •Informed written consent
排除标准
- •Medical or psychiatric conditions resulting in inability of patient to give written consent.
- •ECOG Performance status >2
- •Intracerebral metastases or meningeal carcinomatosis
- •Unresolved bowel obstruction
- •Uncontrolled angina pectoris, heart failure (New York heart classification 3 or 4).
- •Pregnancy/lactation
- •Previous malignancy other than adequately treated basal cell carcinoma of the skin or cervical carcinoma in situ.
结局指标
主要结局
Disease stabilization rate or tumour marker response
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI TumoursUpper Gastrointestinal TumoursNCT00220168Royal Marsden NHS Foundation Trust33
已完成
2 期
Fluorouracil and folinic acid (FOLFIRI) plus an endothelin receptor antagonist (ERAT) in advanced colorectal cancer patients who have failed on oxaliplatin-containing chemotherapyocally advanced and/or metastatic colorectal cancer (mCRC)Malignant neoplasm of rectosigmoid junctionCancerISRCTN73199181Cardiff University (UK)122
进行中（未招募）
1 期
A randomised phase II study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of Oxaliplatin-containing chemotherapy - FOLFIRI plus ZD4054 in colorectal cancers refractory to oxaliplatiMetastatic Colorectal CancerEUCTR2009-012151-23-GBCardiff University122
进行中（未招募）
不适用
Phase II study of irinotecan weekly in combination with trastuzumab in patientswith locally advanced or metastatic HER2-positive breast cancer and increased cancer cell copy number of TOP1”Metastatic breast cancerEUCTR2012-002347-23-DKDanish Breast Cancer Group (DBCG)
终止
3 期
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or RectumColorectal CancerNCT00077233Alliance for Clinical Trials in Oncology238